In this clinical topic video, medical oncologist Prof. David Hong shares his insights into recent advances in precision oncology and potential future implications and discusses two new, emerging targets, as well as two established biomarker targets and their recent clinical data.
Watch the video for an overview of:
- Inhibitors for KRAS mutations
- Novel agents targeting patient subsets such as those with MTAP loss
- Tumour-agnostic targets such as NTRK and HER2 and how they continue to evolve and provide clinical benefit across a number of tumour types
Prof. Hong also highlights the importance of molecular profiling to ensure patients receive the most appropriate targeted therapy to improve outcomes.
Clinical takeaways
- Ongoing research is uncovering new, precise, and reliable tumour biomarkers. This has improved advanced precision medicine, promising better outcomes for people with cancer
- Inhibitors for KRAS mutations (e.g. sotorasib/adagrasib) have provided new treatment options for cancer in certain subpopulations (i.e. KRASG12C mutated); other agents targeting specific patient subsets (e.g. those with MTAP loss) may expand targeted therapy options
- Evolving targets like NTRK and HER2 are benefiting multiple cancer types
- The expansion of new biomarkers and targeted therapies highlights the importance of molecular profiling using NGS and knowing which treatment option is best suited to individual patients
Download Slides - PDF 
Duration
Language(s)
1 MIN
May 2025 
Downloadable 
